The Wall Street Journal
Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers
📈
AI Sentiment
Highly Positive
9/10
- Home
- NVO
NVO
Novo Nordisk A/S
as of 03-09-2026 3:52pm EST
$39.68
+$1.13
+2.94%
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 269.6B | IPO Year: | N/A |
| Target Price: | $51.00 | AVG Volume (30 days): | 19.9M |
| Analyst Decision: | Hold | Number of Analysts: | 11 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $35.85 - $82.23 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -3.18% | Revenue Growth (next year): | 4.39% |
| P/E Ratio: | 13.60 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | -20.11% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
The Wall Street Journal
Hims & Hers Stock Surges as Novo Nordisk Deal Ends Legal Dispute
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Sector Update: Health Care Stocks Decline Premarket Monday
📉
AI Sentiment
Negative
3/10
MT Newswires
Hims & Hers to Provide Ozempic and Wegovy; Novo Nordisk Drops Lawsuit; Shares Soar Pre-Bell
âž–
AI Sentiment
Neutral
5/10
Quartz
Hims & Hers will sell real Ozempic in deal with Novo Nordisk
📈
AI Sentiment
Highly Positive
10/10
MT Newswires
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Oil Price Surge
âž–
AI Sentiment
Neutral
4/10
Compare NVO vs Leading Stocks
See how NVO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.